S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)

SI-BONE (SIBN) Stock Price, News & Analysis

$19.42
+0.08 (+0.41%)
(As of 04:24 PM ET)
Compare
Today's Range
$18.93
$19.50
50-Day Range
$15.75
$21.19
52-Week Range
$11.23
$29.51
Volume
375,376 shs
Average Volume
354,740 shs
Market Capitalization
$786.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.17

SI-BONE MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
39.8% Upside
$27.17 Price Target
Short Interest
Healthy
2.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.44
Upright™ Environmental Score
News Sentiment
0.33mentions of SI-BONE in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$761,439 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.14) to ($0.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

396th out of 943 stocks

Surgical & Medical Instruments Industry

50th out of 92 stocks


SIBN stock logo

About SI-BONE Stock (NASDAQ:SIBN)

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and distributors. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

SIBN Stock Price History

SIBN Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
SI-BONE Inc SIBN
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Sizing Up SI-BONE After Q3 Earnings
SI-BONE earnings preview: what Wall Street is expecting
Si-Bone (SIBN) Upgraded to Buy: Here's Why
Has SiBone (SIBN) Outpaced Other Medical Stocks This Year?
See More Headlines
Receive SIBN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SIBN
Fax
N/A
Employees
357
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$27.17
High Stock Price Target
$33.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+39.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-61,260,000.00
Pretax Margin
-32.98%

Debt

Sales & Book Value

Annual Sales
$106.41 million
Book Value
$2.85 per share

Miscellaneous

Free Float
38,314,000
Market Cap
$786.92 million
Optionable
Not Optionable
Beta
1.01

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives















SIBN Stock Analysis - Frequently Asked Questions

Should I buy or sell SI-BONE stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SIBN shares.
View SIBN analyst ratings
or view top-rated stocks.

What is SI-BONE's stock price target for 2024?

5 brokers have issued 12-month target prices for SI-BONE's stock. Their SIBN share price targets range from $24.00 to $33.00. On average, they predict the company's stock price to reach $27.17 in the next twelve months. This suggests a possible upside of 39.8% from the stock's current price.
View analysts price targets for SIBN
or view top-rated stocks among Wall Street analysts.

How have SIBN shares performed in 2023?

SI-BONE's stock was trading at $13.60 at the beginning of the year. Since then, SIBN shares have increased by 42.9% and is now trading at $19.43.
View the best growth stocks for 2023 here
.

When is SI-BONE's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our SIBN earnings forecast
.

How were SI-BONE's earnings last quarter?

SI-BONE, Inc. (NASDAQ:SIBN) released its earnings results on Monday, November, 6th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.08. The business earned $34.01 million during the quarter, compared to the consensus estimate of $32.23 million. SI-BONE had a negative trailing twelve-month return on equity of 32.05% and a negative net margin of 32.98%.

What is Jeffrey Dunn's approval rating as SI-BONE's CEO?

10 employees have rated SI-BONE Chief Executive Officer Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among the company's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of SI-BONE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), RTX (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX).

When did SI-BONE IPO?

(SIBN) raised $84 million in an initial public offering (IPO) on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Who are SI-BONE's major shareholders?

SI-BONE's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Brown Advisory Inc. (10.32%), Morgan Stanley (2.00%), Allspring Global Investments Holdings LLC (1.75%), Wellington Management Group LLP (1.50%), Impax Asset Management Group plc (1.23%) and Paradigm Capital Management Inc. NY (0.96%). Insiders that own company stock include Anshul Maheshwari, Anthony J Recupero, Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeffrey W Dunn, Jeryl L Hilleman, Jeryl L Hilleman, John Gordon Freund, Laura Francis, Michael A Pisetsky and Michael A Pisetsky.
View institutional ownership trends
.

How do I buy shares of SI-BONE?

Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does SI-BONE have any subsidiaries?
The following companies are subsidiares of SI-BONE: SI-BONE Deutschland GmbH, SI-BONE S.R.L., and SI-BONE UK LTD.
Read More
This page (NASDAQ:SIBN) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -